BioMarin (BMRN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

BioMarin Pharmaceutical (BMRN) reported $745.74 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 28.3$0.91 for the same period compares to $0.46 a year ago. The reported revenue compares to the Zacks Consensus Estimate of$706.95 million, representing a surprise of +5.49%. The company delivered an EPS surprise of +16.67%, with the consensus EPS estimate being $0.78. While investors scrutinize revenue and earnings changes year-over-year and how they ...